Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

Lilly’s total revenues for the fourth quarter fell short of expectations due to lower-than-expected sales of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity.

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... and make sure their analysis is clear and in no way misleading or deceptive.

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...

There is no oral version of tirzepatide sold in the world today, as it is administered only by injection (Zepbound® and Mounjaro®). Lexaria has completed other research with oral ...

BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk (NYSE:NVO)'s Wegovy and Ozempic, which has led to lower-than-expected demand for Eli Lilly's weight loss and diabetes ...

This can save you up to $150 per month on your prescription, and there is no income limit to qualify ... For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the ...